Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
67
EQ Quote, Financials, Valuation and Earnings
Last price:
$1.61
Seasonality move
:
25.95%
Day range:
$1.39 - $1.70
52-week range:
$0.27 - $2.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
15.77x
P/B ratio:
3.17x
Volume:
1.6M
Avg. volume:
689.9K
1-year change:
149.3%
Market cap:
$98M
Revenue:
$41.1M
EPS (TTM):
-$0.63
Analysts' Opinion
-
Consensus RatingEquillium, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.50, Equillium, Inc. has an estimated upside of 55.28% from its current price of $1.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.00 representing 100% downside risk from its current price of $1.61.
Fair Value
-
According to the consensus of 3 analysts, Equillium, Inc. has 55.28% upside to fair value with a price target of $2.50 per share.
EQ vs. S&P 500
-
Over the past 5 trading days, Equillium, Inc. has overperformed the S&P 500 by 44.3% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Equillium, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Equillium, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Equillium, Inc. reported revenues of --.
Earnings Growth
-
Equillium, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Equillium, Inc. reported earnings per share of -$0.06.
Enterprise value:
65.7M
EV / Invested capital:
2.07x
Price / LTM sales:
15.77x
EV / EBIT:
--
EV / Revenue:
14.95x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-2.86x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$4.3M
Return On Assets:
-98.6%
Net Income Margin (TTM):
-555.94%
Return On Equity:
-137.47%
Return On Invested Capital:
-134.17%
Operating Margin:
-106.97%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $42.6M | $45.9M | $4.4M | $12.2M | -- | |
| Gross Profit | $42.5M | $45.8M | $4.3M | $12.1M | -$28K | |
| Operating Income | -$9.3M | -$6.8M | -$24.4M | -$679K | -$4.6M | |
| EBITDA | -$9.2M | -$6.6M | -$24.2M | -$644K | -$4.5M | |
| Diluted EPS | -$0.24 | -$0.13 | -$0.63 | -$0.00 | -$0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $92.2M | $46.8M | $53.9M | $33.6M | $33.6M | |
| Total Assets | $92.5M | $48.6M | $55.2M | $34.5M | $34.5M | |
| Current Liabilities | $7.8M | $14.9M | $28.2M | $11.1M | $3.1M | |
| Total Liabilities | $16.7M | $20.5M | $31.1M | $11.3M | $3.6M | |
| Total Equity | $75.8M | $28.2M | $24.1M | $23.2M | $30.9M | |
| Total Debt | $10.1M | $11.3M | $498K | $223K | $473K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $11.6M | -$21.4M | -$22.9M | -$7.7M | -$8.4M | |
| Cash From Investing | $7.8M | $2.3M | $10.5M | $12M | -- | |
| Cash From Financing | -$10.7M | $170K | $30.2M | -- | $30.1M | |
| Free Cash Flow | $11.6M | -$21.5M | -$22.9M | -$7.7M | -$8.4M | |
EQ
Sector
Market Cap
$98M
$28M
Price % of 52-Week High
68.51%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-34.86%
-1.54%
1-Year Price Total Return
149.3%
-17.48%
Beta (5-Year)
1.922
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.26
200-day SMA
Buy
Level
$0.87
Bollinger Bands (100)
Buy
Level
0.94 - 1.64
Chaikin Money Flow
Sell
Level
-408.8K
20-day SMA
Buy
Level
$1.07
Relative Strength Index (RSI14)
Buy
Level
69.49
ADX Line
Buy
Level
25.03
Williams %R
Sell
Level
-10.4106
50-day SMA
Buy
Level
$1.15
MACD (12, 26)
Buy
Level
0.09
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
3.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.7466)
Sell
CA Score
(Annual)
Level (-0.8084)
Sell
Beneish M-Score
(Annual)
Level (-0.1158)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (2.6034)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March 2017 and is headquartered in La Jolla, CA.
Stock Forecast FAQ
In the current month, EQ has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The EQ average analyst price target in the past 3 months is $2.50.
-
Where Will Equillium, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Equillium, Inc. share price will rise to $2.50 per share over the next 12 months.
-
What Do Analysts Say About Equillium, Inc.?
Analysts are divided on their view about Equillium, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Equillium, Inc. is a Sell and believe this share price will drop from its current level to $1.00.
-
What Is Equillium, Inc.'s Price Target?
The price target for Equillium, Inc. over the next 1-year time period is forecast to be $2.50 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is EQ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Equillium, Inc. is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of EQ?
You can purchase shares of Equillium, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Equillium, Inc. shares.
-
What Is The Equillium, Inc. Share Price Today?
Equillium, Inc. was last trading at $1.61 per share. This represents the most recent stock quote for Equillium, Inc.. Yesterday, Equillium, Inc. closed at $1.61 per share.
-
How To Buy Equillium, Inc. Stock Online?
In order to purchase Equillium, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get EQ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EQ
Sector
P/E ratio
--
23.89x
PEG ratio
-0.01x
-0.01x
P/B ratio
3.17x
1.82x
Price / LTM sales
15.77x
1.60x
Growth Metrics
EQ
Sector
Revenue growth
-100%
4.62%
Earnings growth
-32300%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$0.22
-$0.21
Profitability
EQ
Sector
Profitability FY 2024
$41M
$3.5M
Return on invested capital
-134.17%
-31.77%
Return on assets
-98.6%
-27.96%
Return on equity
-137.47%
-37.63%
Earnings Date
Last Earnings Date
May
15
Next Earnings Date
Dec
25
Estimated Next Earnings Date
Mar
26
Balance Sheet
EQ
Sector
Total cash
$33.1M
$26.3M
Short term investments
$4.5M
$25.7M
Total assets
$25.7M
$78M
Long term debt
$473K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
